Concepts (262)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urinary Incontinence, Stress | 12 | 2013 | 33 | 1.320 |
Why?
|
| BCG Vaccine | 3 | 2021 | 112 | 0.850 |
Why?
|
| Immunization, Secondary | 1 | 2021 | 113 | 0.680 |
Why?
|
| Norpregnadienes | 2 | 2010 | 3 | 0.680 |
Why?
|
| Contraception, Postcoital | 2 | 2010 | 3 | 0.680 |
Why?
|
| Mortality | 1 | 2021 | 257 | 0.630 |
Why?
|
| Pelvic Floor | 4 | 2007 | 39 | 0.580 |
Why?
|
| Tuberculosis | 7 | 2021 | 557 | 0.570 |
Why?
|
| Leprosy | 6 | 2021 | 20 | 0.550 |
Why?
|
| Disease Transmission, Infectious | 3 | 2013 | 86 | 0.550 |
Why?
|
| Urinary Incontinence | 7 | 2024 | 78 | 0.540 |
Why?
|
| Vaccination | 4 | 2021 | 1017 | 0.540 |
Why?
|
| Malawi | 14 | 2021 | 423 | 0.480 |
Why?
|
| Exercise Therapy | 2 | 2007 | 184 | 0.470 |
Why?
|
| Uterine Prolapse | 6 | 2008 | 21 | 0.410 |
Why?
|
| Cholera | 1 | 2013 | 30 | 0.400 |
Why?
|
| Family Characteristics | 1 | 2013 | 91 | 0.380 |
Why?
|
| Longitudinal Studies | 4 | 2013 | 1501 | 0.370 |
Why?
|
| Anesthesiology | 1 | 2013 | 100 | 0.360 |
Why?
|
| Gynecologic Surgical Procedures | 5 | 2014 | 63 | 0.360 |
Why?
|
| Pregnancy, Unwanted | 1 | 2010 | 4 | 0.350 |
Why?
|
| Puerperal Disorders | 2 | 2007 | 47 | 0.330 |
Why?
|
| Anesthesia | 1 | 2013 | 209 | 0.330 |
Why?
|
| Contraceptives, Postcoital, Hormonal | 1 | 2010 | 1 | 0.330 |
Why?
|
| Postpartum Period | 3 | 2007 | 231 | 0.310 |
Why?
|
| Fecal Incontinence | 5 | 2024 | 78 | 0.310 |
Why?
|
| Mycobacterium leprae | 2 | 2021 | 4 | 0.300 |
Why?
|
| Voluntary Health Agencies | 1 | 2007 | 5 | 0.280 |
Why?
|
| Condylomata Acuminata | 1 | 2007 | 15 | 0.280 |
Why?
|
| Adult | 31 | 2021 | 31576 | 0.250 |
Why?
|
| Forests | 2 | 2023 | 15 | 0.250 |
Why?
|
| Pelvic Floor Disorders | 2 | 2024 | 12 | 0.250 |
Why?
|
| Female | 46 | 2024 | 70672 | 0.250 |
Why?
|
| Counseling | 1 | 2007 | 235 | 0.240 |
Why?
|
| Ecosystem | 2 | 2023 | 106 | 0.240 |
Why?
|
| Vaginosis, Bacterial | 2 | 2019 | 19 | 0.220 |
Why?
|
| Health Care Costs | 1 | 2007 | 407 | 0.220 |
Why?
|
| Middle Aged | 27 | 2021 | 28827 | 0.220 |
Why?
|
| Mycobacterium tuberculosis | 2 | 2001 | 413 | 0.210 |
Why?
|
| Tuberculin Test | 2 | 2006 | 123 | 0.210 |
Why?
|
| Follow-Up Studies | 8 | 2021 | 5370 | 0.210 |
Why?
|
| Pelvic Organ Prolapse | 2 | 2014 | 32 | 0.210 |
Why?
|
| Trees | 2 | 2023 | 20 | 0.210 |
Why?
|
| Humans | 52 | 2024 | 132045 | 0.210 |
Why?
|
| Fasciitis, Necrotizing | 1 | 2003 | 30 | 0.200 |
Why?
|
| Treatment Outcome | 14 | 2021 | 12882 | 0.200 |
Why?
|
| Immunogenicity, Vaccine | 2 | 2021 | 114 | 0.200 |
Why?
|
| Adolescent | 19 | 2021 | 20513 | 0.200 |
Why?
|
| Biodiversity | 2 | 2023 | 88 | 0.200 |
Why?
|
| Aged | 23 | 2021 | 21317 | 0.200 |
Why?
|
| Anal Canal | 3 | 2007 | 82 | 0.190 |
Why?
|
| Elephantiasis, Filarial | 1 | 2002 | 13 | 0.190 |
Why?
|
| Urogenital Surgical Procedures | 3 | 2008 | 11 | 0.190 |
Why?
|
| Antiviral Agents | 1 | 2007 | 823 | 0.190 |
Why?
|
| Vagina | 4 | 2013 | 204 | 0.180 |
Why?
|
| Child, Preschool | 12 | 2021 | 14821 | 0.170 |
Why?
|
| DNA Fingerprinting | 1 | 2001 | 110 | 0.170 |
Why?
|
| Smallpox | 1 | 2020 | 11 | 0.170 |
Why?
|
| Pregnancy | 10 | 2013 | 7552 | 0.160 |
Why?
|
| Smoke Inhalation Injury | 1 | 2000 | 6 | 0.160 |
Why?
|
| Accident Prevention | 1 | 2000 | 9 | 0.160 |
Why?
|
| Smallpox Vaccine | 1 | 2020 | 38 | 0.160 |
Why?
|
| Fires | 1 | 2000 | 12 | 0.160 |
Why?
|
| Child | 17 | 2021 | 25779 | 0.160 |
Why?
|
| Streptococcal Vaccines | 1 | 2019 | 18 | 0.160 |
Why?
|
| Bacterial Capsules | 1 | 2019 | 41 | 0.150 |
Why?
|
| Hypersensitivity, Delayed | 2 | 1999 | 33 | 0.150 |
Why?
|
| Burns | 1 | 2000 | 101 | 0.150 |
Why?
|
| Prevalence | 8 | 2012 | 2659 | 0.150 |
Why?
|
| Double-Blind Method | 2 | 2021 | 1644 | 0.150 |
Why?
|
| Contact Tracing | 1 | 1999 | 56 | 0.150 |
Why?
|
| England | 2 | 2013 | 63 | 0.140 |
Why?
|
| Young Adult | 5 | 2021 | 9934 | 0.130 |
Why?
|
| Disease Susceptibility | 1 | 1998 | 292 | 0.130 |
Why?
|
| Male | 21 | 2021 | 64891 | 0.130 |
Why?
|
| Streptococcal Infections | 1 | 2019 | 247 | 0.130 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 1999 | 224 | 0.130 |
Why?
|
| Urinary Bladder | 4 | 2008 | 253 | 0.120 |
Why?
|
| Oral Health | 1 | 2014 | 27 | 0.110 |
Why?
|
| Athletic Performance | 1 | 2014 | 14 | 0.110 |
Why?
|
| Population Surveillance | 2 | 2012 | 414 | 0.110 |
Why?
|
| Delivery, Obstetric | 2 | 2007 | 260 | 0.110 |
Why?
|
| Drug Therapy, Combination | 3 | 2007 | 1165 | 0.110 |
Why?
|
| Haemophilus influenzae type b | 1 | 2013 | 5 | 0.110 |
Why?
|
| Patient Education as Topic | 2 | 2007 | 464 | 0.110 |
Why?
|
| Haemophilus Vaccines | 1 | 2013 | 32 | 0.110 |
Why?
|
| Chlamydia trachomatis | 1 | 2013 | 27 | 0.100 |
Why?
|
| Infant | 8 | 2013 | 13112 | 0.100 |
Why?
|
| Immunization Schedule | 1 | 2013 | 107 | 0.100 |
Why?
|
| Gonorrhea | 1 | 2013 | 40 | 0.100 |
Why?
|
| Chlamydia Infections | 1 | 2013 | 49 | 0.100 |
Why?
|
| Papanicolaou Test | 1 | 2013 | 37 | 0.100 |
Why?
|
| Vaginal Smears | 1 | 2013 | 53 | 0.100 |
Why?
|
| Haemophilus Infections | 1 | 2013 | 96 | 0.100 |
Why?
|
| Stochastic Processes | 1 | 2013 | 38 | 0.100 |
Why?
|
| History, 19th Century | 1 | 2013 | 120 | 0.100 |
Why?
|
| Anti-Retroviral Agents | 2 | 2012 | 147 | 0.100 |
Why?
|
| Antigens, Bacterial | 1 | 1994 | 325 | 0.100 |
Why?
|
| Surveys and Questionnaires | 6 | 2007 | 3977 | 0.100 |
Why?
|
| Combined Modality Therapy | 2 | 2007 | 1292 | 0.090 |
Why?
|
| Quality of Life | 5 | 2008 | 2150 | 0.090 |
Why?
|
| Suburethral Slings | 2 | 2008 | 8 | 0.090 |
Why?
|
| Health Surveys | 1 | 2012 | 259 | 0.090 |
Why?
|
| Contraceptives, Postcoital | 1 | 2010 | 1 | 0.090 |
Why?
|
| Ovulation Inhibition | 1 | 2010 | 1 | 0.090 |
Why?
|
| Administration, Oral | 2 | 2010 | 709 | 0.090 |
Why?
|
| Contraceptives, Oral, Synthetic | 1 | 2010 | 5 | 0.090 |
Why?
|
| Disease Outbreaks | 1 | 2013 | 329 | 0.090 |
Why?
|
| Levonorgestrel | 1 | 2010 | 20 | 0.090 |
Why?
|
| Unsafe Sex | 1 | 2010 | 25 | 0.090 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2010 | 31 | 0.090 |
Why?
|
| Odds Ratio | 3 | 2013 | 1256 | 0.090 |
Why?
|
| Public Health | 1 | 2013 | 282 | 0.080 |
Why?
|
| Patient Dropouts | 1 | 2010 | 52 | 0.080 |
Why?
|
| Parity | 2 | 2007 | 86 | 0.080 |
Why?
|
| Time Factors | 3 | 2010 | 6411 | 0.080 |
Why?
|
| Menstrual Cycle | 1 | 2010 | 36 | 0.080 |
Why?
|
| Age Distribution | 2 | 2002 | 433 | 0.080 |
Why?
|
| Cross-Sectional Studies | 4 | 2009 | 3734 | 0.080 |
Why?
|
| Dapsone | 1 | 1988 | 6 | 0.070 |
Why?
|
| Surgical Mesh | 2 | 2013 | 70 | 0.070 |
Why?
|
| Urethra | 3 | 2013 | 89 | 0.070 |
Why?
|
| Trichloroacetic Acid | 1 | 2007 | 5 | 0.070 |
Why?
|
| Cohort Studies | 5 | 2010 | 5142 | 0.070 |
Why?
|
| Urologic Surgical Procedures | 1 | 2008 | 59 | 0.070 |
Why?
|
| Cryotherapy | 1 | 2007 | 21 | 0.070 |
Why?
|
| Aminoquinolines | 1 | 2007 | 34 | 0.070 |
Why?
|
| Tinidazole | 1 | 2007 | 1 | 0.070 |
Why?
|
| Antitrichomonal Agents | 1 | 2007 | 10 | 0.070 |
Why?
|
| Rifampin | 1 | 1988 | 125 | 0.070 |
Why?
|
| Cicatrix | 1 | 1989 | 123 | 0.070 |
Why?
|
| Age Factors | 4 | 2001 | 2921 | 0.070 |
Why?
|
| Physical Examination | 2 | 2004 | 165 | 0.070 |
Why?
|
| Rural Population | 2 | 2000 | 281 | 0.070 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2009 | 242 | 0.060 |
Why?
|
| Sensitivity and Specificity | 3 | 2013 | 2141 | 0.060 |
Why?
|
| Models, Statistical | 2 | 1999 | 492 | 0.060 |
Why?
|
| Postoperative Complications | 4 | 2013 | 3081 | 0.060 |
Why?
|
| Endosonography | 1 | 2006 | 81 | 0.060 |
Why?
|
| Lacerations | 1 | 2006 | 33 | 0.060 |
Why?
|
| Cesarean Section | 3 | 2007 | 403 | 0.060 |
Why?
|
| Domestic Violence | 1 | 2005 | 12 | 0.060 |
Why?
|
| Preoperative Care | 1 | 2008 | 366 | 0.060 |
Why?
|
| National Institute of Child Health and Human Development (U.S.) | 1 | 2024 | 9 | 0.060 |
Why?
|
| Sex Offenses | 1 | 2005 | 48 | 0.060 |
Why?
|
| Spouses | 1 | 2005 | 73 | 0.060 |
Why?
|
| United Kingdom | 2 | 2009 | 234 | 0.060 |
Why?
|
| Mass Screening | 1 | 2010 | 827 | 0.060 |
Why?
|
| Abortion, Induced | 1 | 2005 | 80 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2013 | 1247 | 0.050 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2009 | 496 | 0.050 |
Why?
|
| Truth Disclosure | 1 | 2005 | 105 | 0.050 |
Why?
|
| Depressive Disorder, Major | 1 | 2009 | 469 | 0.050 |
Why?
|
| Brazil | 1 | 2023 | 138 | 0.050 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2004 | 138 | 0.050 |
Why?
|
| Medical History Taking | 1 | 2004 | 114 | 0.050 |
Why?
|
| Texas | 3 | 2007 | 3647 | 0.050 |
Why?
|
| Research Design | 2 | 2024 | 750 | 0.050 |
Why?
|
| Debridement | 1 | 2003 | 93 | 0.050 |
Why?
|
| Influenza, Human | 1 | 2009 | 699 | 0.050 |
Why?
|
| Methods | 2 | 1996 | 125 | 0.050 |
Why?
|
| Infant, Newborn | 3 | 2001 | 8501 | 0.050 |
Why?
|
| Testicular Hydrocele | 1 | 2002 | 3 | 0.050 |
Why?
|
| Microfilariae | 1 | 2002 | 3 | 0.050 |
Why?
|
| Lymphedema | 1 | 2002 | 21 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2003 | 3655 | 0.050 |
Why?
|
| Aged, 80 and over | 5 | 2012 | 7097 | 0.050 |
Why?
|
| Case-Control Studies | 4 | 2013 | 3421 | 0.050 |
Why?
|
| Hysterectomy, Vaginal | 1 | 2001 | 19 | 0.050 |
Why?
|
| Risk Factors | 5 | 2007 | 10834 | 0.040 |
Why?
|
| Sex Factors | 2 | 2000 | 1350 | 0.040 |
Why?
|
| Netherlands | 1 | 2001 | 46 | 0.040 |
Why?
|
| Incidence | 4 | 2012 | 3362 | 0.040 |
Why?
|
| Molecular Epidemiology | 1 | 2001 | 146 | 0.040 |
Why?
|
| Singapore | 1 | 2020 | 16 | 0.040 |
Why?
|
| Monkeypox virus | 1 | 2020 | 5 | 0.040 |
Why?
|
| London | 1 | 2020 | 15 | 0.040 |
Why?
|
| United States | 2 | 2024 | 11620 | 0.040 |
Why?
|
| Ghana | 1 | 2020 | 25 | 0.040 |
Why?
|
| Israel | 1 | 2020 | 47 | 0.040 |
Why?
|
| Nigeria | 1 | 2020 | 77 | 0.040 |
Why?
|
| Epidemiologic Methods | 2 | 1998 | 97 | 0.040 |
Why?
|
| Alabama | 1 | 2000 | 47 | 0.040 |
Why?
|
| Housing | 1 | 2000 | 54 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2001 | 433 | 0.040 |
Why?
|
| Risk | 2 | 2013 | 763 | 0.040 |
Why?
|
| Peru | 1 | 2019 | 56 | 0.040 |
Why?
|
| Vaccines, Conjugate | 1 | 2019 | 83 | 0.040 |
Why?
|
| Wales | 1 | 1998 | 8 | 0.040 |
Why?
|
| Tropical Climate | 1 | 2019 | 51 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2024 | 550 | 0.040 |
Why?
|
| Streptococcus agalactiae | 1 | 2019 | 103 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2003 | 3067 | 0.040 |
Why?
|
| Sex Distribution | 1 | 1999 | 325 | 0.040 |
Why?
|
| Life Style | 1 | 2001 | 455 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2002 | 1228 | 0.030 |
Why?
|
| Health Status Indicators | 2 | 2008 | 128 | 0.030 |
Why?
|
| Urinary Bladder Diseases | 2 | 2006 | 34 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2007 | 3019 | 0.030 |
Why?
|
| Episiotomy | 2 | 2007 | 17 | 0.030 |
Why?
|
| Alcohol Drinking | 1 | 2000 | 359 | 0.030 |
Why?
|
| Tinea Versicolor | 1 | 1996 | 1 | 0.030 |
Why?
|
| Antibodies, Bacterial | 1 | 2019 | 406 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2019 | 803 | 0.030 |
Why?
|
| Interviews as Topic | 2 | 2010 | 428 | 0.030 |
Why?
|
| Models, Biological | 1 | 2001 | 1464 | 0.030 |
Why?
|
| Urodynamics | 2 | 2006 | 38 | 0.030 |
Why?
|
| Oral Hygiene | 1 | 2014 | 11 | 0.030 |
Why?
|
| Colposcopy | 1 | 2014 | 16 | 0.030 |
Why?
|
| Patient Compliance | 2 | 2007 | 474 | 0.030 |
Why?
|
| Defecation | 1 | 2014 | 34 | 0.030 |
Why?
|
| Smoking | 1 | 2000 | 940 | 0.030 |
Why?
|
| Sacrococcygeal Region | 1 | 2014 | 36 | 0.030 |
Why?
|
| Skin Tests | 1 | 1994 | 80 | 0.030 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2014 | 95 | 0.030 |
Why?
|
| Patient Satisfaction | 2 | 2008 | 487 | 0.030 |
Why?
|
| Retrospective Studies | 3 | 2008 | 17307 | 0.030 |
Why?
|
| Athletes | 1 | 2014 | 73 | 0.030 |
Why?
|
| Survival Rate | 1 | 1999 | 2161 | 0.030 |
Why?
|
| Immunity, Cellular | 1 | 1994 | 204 | 0.030 |
Why?
|
| Neisseria gonorrhoeae | 1 | 2013 | 16 | 0.030 |
Why?
|
| Longitudinal Ligaments | 1 | 2013 | 3 | 0.030 |
Why?
|
| Asymptomatic Diseases | 1 | 2013 | 86 | 0.030 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2013 | 71 | 0.030 |
Why?
|
| Culture Media | 1 | 2013 | 183 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2013 | 360 | 0.020 |
Why?
|
| Health Behavior | 1 | 2014 | 400 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2003 | 2578 | 0.020 |
Why?
|
| Reoperation | 1 | 2014 | 808 | 0.020 |
Why?
|
| Health Promotion | 1 | 2014 | 404 | 0.020 |
Why?
|
| Ultrasonography | 1 | 1996 | 985 | 0.020 |
Why?
|
| Sexual Behavior | 1 | 2012 | 250 | 0.020 |
Why?
|
| Health Status | 1 | 2012 | 406 | 0.020 |
Why?
|
| Health Status Disparities | 1 | 2012 | 251 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2012 | 905 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2009 | 253 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 1988 | 258 | 0.020 |
Why?
|
| Urinary Catheterization | 1 | 1988 | 87 | 0.020 |
Why?
|
| Urinary Incontinence, Urge | 1 | 2007 | 5 | 0.020 |
Why?
|
| Translations | 1 | 2007 | 18 | 0.020 |
Why?
|
| Urination | 1 | 2007 | 26 | 0.020 |
Why?
|
| Hot Temperature | 1 | 1988 | 143 | 0.020 |
Why?
|
| Flatulence | 1 | 2006 | 7 | 0.020 |
Why?
|
| Mutation | 1 | 2001 | 6250 | 0.020 |
Why?
|
| Perineum | 1 | 2006 | 48 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2007 | 746 | 0.020 |
Why?
|
| Logistic Models | 1 | 2010 | 1841 | 0.010 |
Why?
|
| Language | 1 | 2007 | 223 | 0.010 |
Why?
|
| Pain | 1 | 1988 | 461 | 0.010 |
Why?
|
| Skin | 1 | 1988 | 540 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2007 | 1686 | 0.010 |
Why?
|
| Psychometrics | 1 | 2007 | 694 | 0.010 |
Why?
|
| Random Allocation | 1 | 2003 | 431 | 0.010 |
Why?
|
| Suture Techniques | 1 | 2003 | 180 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2007 | 1708 | 0.010 |
Why?
|
| Medical Records | 1 | 2001 | 190 | 0.010 |
Why?
|
| Animals | 1 | 2002 | 35064 | 0.010 |
Why?
|
| Hospital Costs | 1 | 2001 | 182 | 0.010 |
Why?
|
| HIV Infections | 1 | 2012 | 2020 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2008 | 6509 | 0.010 |
Why?
|
| Length of Stay | 1 | 2001 | 1375 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 1996 | 329 | 0.010 |
Why?
|